» Articles » PMID: 33485835

Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis

Overview
Publisher Elsevier
Specialty Oncology
Date 2021 Jan 24
PMID 33485835
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Despite significant improvements in multiple myeloma (MM) treatment modalities, patient mortality early in the course of disease has been identified as a persistent phenomenon with variable reported rates and causes. Trends in early mortality over time have not been clearly defined.

Patients And Methods: The Surveillance Epidemiology and End Results (SEER) database was used to identify adult patients with MM between 1975 and 2015. Association of available sociodemographic factors with all-cause and MM-specific early mortality (death within 6 months after the diagnosis of MM) was conducted by multivariate analysis. Trends in early mortality were studied by joinpoint regression analysis.

Results: Of the 90,975 MM cases included in this analysis, early mortality was noted in 21%. Median age was 68 years overall, and 75 years for the early mortality cohort (P < .01). The most common causes of death for early mortality were MM itself, followed by cardiovascular, infections, and renal failure. Male gender, "other" race/ethnicity group, advancing age, and West, Midwest or South regions (reference Northeast) were associated with increased risk of both all-cause and MM-specific early mortality. Joinpoint regression analysis of trends data resulted in 1 joinpoint for all-cause 6-month mortality (2006-2015), while 2 joinpoints were noticed for myeloma-specific 6-month mortality (1975-1987 and 2003-2015).

Conclusion: Early mortality remains a significant unmet need for MM patient care, despite improving trends in recent years. Understanding the factors associated with early mortality can help develop individualized plans of patient care and mitigate circumstances that may contribute to early mortality among MM patients.

Citing Articles

Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.

Zhuge L, Lin X, Fan Z, Jia M, Lin C, Zhu M Front Public Health. 2025; 13:1527198.

PMID: 39931304 PMC: 11807829. DOI: 10.3389/fpubh.2025.1527198.


Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.

Carvalho L, Assis R, Montenegro C, da Rosa M, Pereira M, Pitta M Int J Mol Sci. 2025; 25(24.

PMID: 39769262 PMC: 11676459. DOI: 10.3390/ijms252413499.


Real world evidence of epidemiological trends, clinical presentation, and prognostic outcomes of multiple myeloma (2007-2021).

Elsabah H, El Omri H, Habas E, Y Taha R, A ElKourashy S, Ibrahim F Front Med (Lausanne). 2024; 11:1338552.

PMID: 38444413 PMC: 10912627. DOI: 10.3389/fmed.2024.1338552.


Competing risk analysis of cardiovascular mortality in multiple myeloma survivors.

Chen G, Guo H, Lin J, Luo S, Xu S Transl Cancer Res. 2024; 12(12):3314-3326.

PMID: 38197077 PMC: 10774068. DOI: 10.21037/tcr-23-1213.


Predictors of health-related quality of life of the patients treated for MM: the first study in the Palestinian healthcare system.

Shawahna R, Amer R, Salameh H, Shawahna A, Aljondy M, Zain-Aldain M Ann Hematol. 2023; 102(12):3543-3554.

PMID: 37801084 DOI: 10.1007/s00277-023-05482-1.